These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 19920107

  • 1. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
    Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM, Balis FM.
    Clin Cancer Res; 2009 Dec 01; 15(23):7361-7. PubMed ID: 19920107
    [Abstract] [Full Text] [Related]

  • 2. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.
    Spunt SL, Irving H, Frost J, Sender L, Guo M, Yang BB, Dreiling L, Santana VM.
    J Clin Oncol; 2010 Mar 10; 28(8):1329-36. PubMed ID: 20142595
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
    Yang BB, Kido A.
    Clin Pharmacokinet; 2011 May 10; 50(5):295-306. PubMed ID: 21456630
    [Abstract] [Full Text] [Related]

  • 4. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, International Pegfilgrastim 749 Study Group.
    Ann Oncol; 2003 Jan 10; 14(1):29-35. PubMed ID: 12488289
    [Abstract] [Full Text] [Related]

  • 5. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.
    Clin Ther; 2009 Jan 10; 31 Pt 2():2388-95. PubMed ID: 20110048
    [Abstract] [Full Text] [Related]

  • 6. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
    Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC.
    Ann Oncol; 2002 Jun 10; 13(6):903-9. PubMed ID: 12123336
    [Abstract] [Full Text] [Related]

  • 7. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
    Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC.
    J Clin Oncol; 2003 Feb 01; 21(3):514-9. PubMed ID: 12560443
    [Abstract] [Full Text] [Related]

  • 8. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma.
    Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C.
    J Pediatr Hematol Oncol; 2005 Aug 01; 27(8):449-51. PubMed ID: 16096530
    [Abstract] [Full Text] [Related]

  • 9. Pegfilgrastim.
    Curran MP, Goa KL.
    Drugs; 2002 Aug 01; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC.
    J Clin Oncol; 2002 Feb 01; 20(3):727-31. PubMed ID: 11821454
    [Abstract] [Full Text] [Related]

  • 12. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
    Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J.
    J Manag Care Pharm; 2007 May 01; 13(4):337-48. PubMed ID: 17506600
    [Abstract] [Full Text] [Related]

  • 13. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W, International Study Group.
    Leuk Lymphoma; 2003 Sep 01; 44(9):1503-8. PubMed ID: 14565651
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN.
    Leuk Lymphoma; 2006 Sep 01; 47(9):1813-7. PubMed ID: 17064993
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
    Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A.
    BMC Cancer; 2008 Jul 10; 8():195. PubMed ID: 18616811
    [Abstract] [Full Text] [Related]

  • 17. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
    Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R.
    Clin Lymphoma Myeloma Leuk; 2010 Jun 10; 10(3):186-91. PubMed ID: 20511163
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
    Sohn BS, Jeong JH, Ahn JH, Jung KH, Kim JE, Sohn JH, Koh SJ, Seo JH, Lee KS, Kim SB.
    Invest New Drugs; 2020 Jun 10; 38(3):866-873. PubMed ID: 31728715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.